Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Bayer reshapes with plan to list plastics unit

Published 18/09/2014, 09:51
© Reuters Logo of German drugmaker Bayer is seen in Leverkusen
BAYGN
-
PFE
-
ZTS
-

By Georgina Prodhan

FRANKFURT (Reuters) - Germany's Bayer, plans to list its less profitable plastics business on the stock market in a deal that could value the division at around 10 billion euros (8 billion pounds) as it seeks to focus entirely on healthcare and crop science.

News of the planned spin-off of the MaterialScience unit, which has a core profit margin of 9.5 percent compared with the group's 20.9 percent, lifted Bayer shares to a record high. It follows a wider healthcare industry trend to streamline operations.

"In this way Bayer would position itself as a world-leading company in the field of human, animal and plant health," the company said in a statement, adding that its supervisory board would discuss the plans at a board meeting on Thursday.

Investors have long speculated that Bayer could split its operations, and Jefferies said in a note this week that spinning off MaterialScience would allow the company to focus on building critical mass in animal health, potentially via acquisitions.

They pointed to Zoetis, the previous veterinary division of Pfizer that is now a standalone business, as one possible target.

Shares in Bayer were up 4 percent at 110.50 euros by 0825 BST, lifting the European chemicals index 1.1 percent.

Equinet analysts value the MaterialScience unit, which makes polycarbonate plastics used in products from panoramic luxury-car roofs to blu-ray disks, at almost 10 billion euros while brokerage DZ Bank said it was worth about 11 billion euros.

The unit's adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) tumbled 15 percent in 2013, on sales of 11.2 billion euros, giving it the margin of 9.5 percent.

Healthcare, the company's largest unit, had an adjusted EBITDA margin of 28.2 percent, and smallest unit CropScience had 25.5 percent.

Despite stable volumes and prices, Bayer said it had been unable to pass on MaterialScience's large increases in raw materials costs to its customers.

"The (plastic) business has underperformed the company's life-sciences operations," brokerage Close Brothers Seydler said in a note.

© Reuters. Logo of German drugmaker Bayer is seen in Leverkusen

(Additional reporting by Ben Hirschler in London; editing by Thomas Atkins and Pravin Char)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.